Clik here to view.
Takeda Completes Sale of TachoSil® to Corza Health
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch (“TachoSil®”)...
View ArticleClik here to view.
Exelixis and Adagene Enter into Collaboration and License Agreement to...
ALAMEDA, Calif., SAN FRANCISCO & SUZHOU, China Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s...
View ArticleClik here to view.
Avacta announces AffyXell $7.3 Million Series A Financing
CAMBRIDGE, England & SEOUL, South Korea Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the...
View ArticleClik here to view.
造血器腫瘍遺伝子パネル検査に関する開発および商業化契約締結について
東京 （ビジネスワイヤ） — 大塚製薬株式会社（本社：東京都、代表取締役社長：井上眞、以下「大塚製薬」）と次世代シークエンサーの世界トップ企業であるIllumina, Inc.（本社：米国カリフォルニア州サンディエゴ、CEO：Francis...
View ArticleClik here to view.
Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug...
SHANGHAI & GUILFORD, Conn. Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has...
View ArticleClik here to view.
Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据
阿姆斯特丹 Modra Pharmaceuticals (“Modra”)今日公布了其先导产品ModraDoc006/r正在进行的治疗转移性去势抵抗性前列腺癌(mCRPC)...
View ArticleClik here to view.
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
キオクシア：生命科学研究における大容量データ解析の高速化について
東京 （ビジネスワイヤ） — キオクシア株式会社は生命科学分野の研究向けにSSDを搭載したGPUクラスタと画像解析アルゴリズムを開発し、RNAシークエンシング技術に関する研究における大容量データ解析の高速化に貢献しました。本研究は米国マサチューセッツ工科大学メディアラボSynthetic...
View ArticleClik here to view.
Kioxia Accelerates Analysis of Large-Volume Data in Life Science Research...
TOKYO Kioxia Corporation is pleased to announce its contribution to the acceleration of large-volume data analysis in the research outcomes described in a new paper “Expansion Sequencing: Spatially...
View ArticleClik here to view.
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During...
SOUTHBOROUGH, Mass. Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection...
View ArticleClik here to view.
武田从Ovid Therapeutics获得儿童和成人Dravet综合征和Lennox-Gastaut综合征治疗药物Soticlestat的全球开发和商业化权利
日本大阪和纽约 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)（“武田”）和致力于开发改变神经系统罕见病患者命运药品的生物制药公司Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”)今天宣布，武田已达成一份排他性协议。根据该协议，武田将在协议签署时从Ovid获得开发和商业化在研药物soticlestat...
View ArticleClik here to view.
武田薬品、ドラベ症候群およびレノックス・ガストー症候群の小児・成人患者に対する治療薬候補ソチクレスタットの世界的な開発・商業化権をオビド・セラピューティク...
大阪 & ニューヨーク （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（以下「武田薬品」）と、希少神経疾患患者の生活を大きく変える医薬品の開発に傾倒するバイオ製薬企業のオビド・セラピューティクス（NASDAQ:...
View ArticleClik here to view.
ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement
DUBLIN & TOKUSHIMA, Japan ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro...
View ArticleClik here to view.
ERS GenomicsとセツロテックがCRISPR/Cas9ライセンス契約を締結
ダブリン＆徳島、日本 ERS Genomics Limited （本社：アイルランド ダブリン、以下「ERS社」）と株式会社セツロテック（本社：徳島県徳島市、以下「セツロテック」）は、Emmanuelle Charpentier...
View ArticleClik here to view.
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and...
View ArticleClik here to view.
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare...
View ArticleClik here to view.
武田薬品のグロース＆エマージング マーケッツ ビジネス ユニットは今後10年で2桁台の売上収益成長を目指す1
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（「武田薬品」）は本日、当社のグロース＆エマージング マーケッツ ビジネス ユニット（「GEM BU」）の売上収益成長について、市場を上回る2桁台という意欲的な目標の概要を発表しました。2030会計年度までに、GEM...
View ArticleClik here to view.
武田旗下的增长与新兴市场业务部门力争在未来10年实现双位数营收增长
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（简称“武田”）今日公布了旗下增长与新兴市场业务部门（简称“GEM BU”）高于市场的双位数营收增长目标。在2030财年实现1万亿日元（约合90亿美元）的营收目标相当于GEM BU...
View ArticleClik here to view.
Provectus Algae Appoints CEO of Senti Biosciences to Board to Aid Advancement...
NOOSAVILLE, Australia & SOUTH SAN FRANCISCO, Calif. Provectus Algae (Provectus), an Australian biotechnology company specialising in the optimisation of algae to produce high-value compounds for...
View ArticleClik here to view.
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
SOUTH SAN FRANCISCO, Calif. & LA JOLLA, Calif. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...
View Article